Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798557 | 0.84 | CYP19A1 (0.43) | KDM4EALDH1A1MAPTPARP1MEN1 | |
| SCHEMBL25783488 | 0.82 | KDM4E (0.38) | KDM4EL3MBTL1ALDH1A1NPSR1MAPT | |
| SCHEMBL25783467 | 0.70 | MAPK1 (0.38) | KDM4EALDH1A1MAPTHTR2BHTR5A | |
| SCHEMBL25783474 | 0.70 | NLRP3 (0.39) | KDM4EL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL27949897 | 0.69 | CTSV (0.48) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30475214 | 0.68 | HPGD (0.53) | KDM4EALDH1A1NPSR1MAPTHTR2B | |
| SCHEMBL18461825 | 0.68 | KMT2A (0.50) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL25783407 | 0.67 | NLRP3 (0.39) | KDM4EL3MBTL1ALDH1A1NPSR1HTR2B | |
| SCHEMBL4238212 | 0.67 | HPGD (0.51) | KDM4EALDH1A1NPSR1MAPTHTR2B | |
| SCHEMBL23875575 | 0.67 | KDM4E (0.40) | KDM4EALDH1A1MAPTTDO2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | KDM4E 1282/4885L3MBTL1 1916/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.